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ABSTRACT
Cancer-selective tetra-branched peptides, named NT4, can be coupled to different 
functional units for cancer cell imaging or therapy. NT4 peptides specifically bind to 
lipoprotein receptor-related proteins (LRP) receptors and to heparan sulfate chains 
on membrane proteoglycans and can be efficiently internalized by cancer cells 
expressing these membrane targets. Since binding and internalization of NT4 peptides 
is mediated by specific NT4 receptors on cancer cell membranes and this may allow 
drug resistance produced by drug membrane transporters to be by-passed, we tested 
the ability of drug-armed NT4 to by-pass drug resistance in cancer cell lines.
We found that MTX-conjugated NT4 allows drug resistance to be by-passed in 
MTX-resistant human breast cancer cells lacking expression of folate reduced carrier. 
NT4 peptides appear to be extremely promising cancer-selective targeting agents that 
can be exploited as theranostics in personalized oncological applications.
INTRODUCTION
The effectiveness of any cancer chemotherapy is 
profoundly limited by drug resistance. Drug resistance can 
be divided into two main categories: intrinsic and acquired 
[1]. In intrinsic resistance, cancer cells respond weakly or 
not at all to the drug from the beginning of treatment due 
to pre-existing factors. In acquired resistance, cancer cells, 
which initially respond to the drug, become progressively 
resistant and cease to respond due to many different 
therapy-induced adaptive mechanisms. Though extremely 
problematic, intrinsic drug resistance can be circumvented 
by alternative medical options. Acquired resistance is even 
more problematic, because it is very difficult to predict 
and sometimes involves simultaneous resistance to many 
different chemotherapy drugs, often resulting in multi-
drug-resistant (MDR) tumor variants [1, 2] that call for 
personalized therapy.
Intrinsic and acquired drug resistance both arise 
from genetic and epigenetic modification of cancer cells. 
Drug resistance can be induced in cancer cells by different 
adaptive molecular mechanisms, including modification 
of drug targets, modification of the metabolic pathway 
responsible for drug activation or activity, modification of 
drug influx or efflux, and activation of savage pathways. 
In any case, drug resistance implies modifications to the 
function and/or expression of enzymes or membrane 
transporters. MDR is often associated with overexpression 
of membrane-active transporters responsible for drug 
extrusion out of the cell [3, 4]. 
Different mechanisms account for drug 
internalization by cancer cells. Hydrophobic molecules 
can be passively transported across cell membranes, 
which implies low selectivity and possibly toxicity 
toward healthy cells, as well as a decrease in active drug 
concentration at the tumor site. Specific transporters 
are responsible for cell internalization of important 
cancer chemotherapy drugs that do not passively cross 
cell membranes, like those belonging to the class of 
antifolates, such as methotrexate (MTX) and aminopterin. 
By closely mimicking folate structure, antifolates use 
folate-specific membrane transporters and receptors 
for cell internalization [5]. Two membrane facilitative 
carriers, reduced folate carrier (RFC) and proton-coupled 
folate transporter (PCFT), and three high affinity folate 
receptor glycoproteins (FRα, FRβ and FRγ), all of which 
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are widely expressed by normal tissues, account for 
antifolate cell internalization. RFC is the major transport 
system for antifolate drugs into cancer cells. 
Once internalized, folate analogs are 
polyglutamylated by folylpolyglutamate synthetase, which 
produces stable folate polyglutamates that are retained in 
the cell, since they are poor substrates for folate export 
transporters. The cytotoxic effect of antifolates is exerted 
by inhibition of dihydrofolate reductase (DHFR) and/or 
thymidylate synthase (TS) and blockade of key folate-
dependent enzymes in the interconnected biosynthetic 
pathways of purine, thymidylate and some amino acids, 
like methionine, ultimately resulting in inhibition of DNA 
replication and cell death [5–8]. Adverse effects associated 
with antifolates include severe damage to normal cells 
and organs, narrow therapeutic index, poor selectivity for 
neoplastic cells, and cancer cell resistance to the drugs. 
Intrinsic and acquired resistance to antifolates is 
unfortunately quite a common event and has dramatic 
consequences on cancer therapy efficiency. Resistance 
to antifolates is frequently caused by impaired drug 
membrane transport, caused by low expression or 
mutations in RFC. Alternative or coexisting causes of 
folate resistance are mutations or aberrant expression of 
enzymes of folate metabolism, like folylpolyglutamate 
synthetase, TS and DHFR [5–9]. Overexpression of 
MDR efflux transporters can also account for antifolate 
resistance, although it is important to note that no 
induced overexpression of MDR transporters has ever 
been reported in cancer cell lines selected for antifolate 
resistance [6]. 
In previous studies we investigated the cancer 
selectivity of tetra-branched peptides containing the 
sequence of human neurotensin, which we named NT4. 
We developed theranostic molecules for tumor imaging 
or therapy by coupling NT4 to different functional units 
or liposomes. NT4 peptides bind with high selectivity 
to cells and tissues of different human cancers, such as 
colorectal cancer, pancreas adenocarcinoma and urinary 
bladder cancer, and can efficiently and selectively deliver 
drugs or liposomes for cancer therapy or carry tracers 
for tumor imaging. Using NT4 conjugated to MTX or 
5-floro-2′deoxyuridine, we obtained a significant reduction 
in tumor growth in mice -60% and 50% respectively-, 
compared with that obtained with equal amounts of 
unconjugated drug [10–14]. More recently, we found 
that conjugation of paclitaxel to NT4 led to increased 
therapeutic activity of the drug in an orthotopic model of 
breast cancer in mice, producing tumor regression which 
was not achieved with unconjugated paclitaxel in identical 
experimental conditions [15]. 
The cancer selectivity of NT4 peptides is much 
higher than that of native monomeric neurotensin, which 
unlike NT4 does not discriminate between healthy human 
tissues and cancer [10, 12, 14]. We demonstrated that the 
branched structure gives NT4 the ability to bind sulfated 
glycosaminoglycan (GAG) chains of membrane heparan 
sulfate proteoglycans (HSPG), as well as different 
endocytic receptors of the low density lipoprotein receptor 
(LDLR) family, like LRP1 and LRP6 [16, 17]. LDLR are 
already known to share many heparin-binding ligands with 
HSPG and both families include potential druggable tumor 
markers involved in cancer biology [18–21]. 
Systematic modification of the neurotensin sequence 
in NT4 peptides led to identification of a positively-
charged multimeric motif that mediates interaction with 
heparin and endocytic receptors [16]. By binding to their 
selective targets on cancer cell membranes, NT4 peptides 
inhibit cancer cell adhesion and migration on different 
extra cellular matrix proteins, dramatically affecting the 
directionality and polarity of cell movement [17]. The 
extremely high cancer selectivity that can be achieved 
by targeting sulfated GAGs with NT4 [16, 17] confirms 
the already reported overexpression of these membrane 
receptors in cancer cells [18, 19, 22–25], which renders 
them potential tumor markers and cancer selective targets 
and suggests that NT4 peptides may indeed be selective 
targeting agents for many different cancers.
In previous studies we demonstrate that NT4 
peptides are efficiently internalized by different cancer 
cells and that internalization is strictly dependent on NT4 
membrane targets [10, 12, 14]. This raised the question of 
whether by binding to different membrane receptors on 
cancer cells, and switching to a different internalization 
mechanism, drug-armed NT4 may by-pass drug resistance 
mediated by specific drug membrane transporters.
Since cancer cell resistance to antifolates is often 
caused by mutation or down-regulation of membrane 
folate carriers, we tested whether conjugation to NT4 
might by-pass cancer cell resistance to MTX. Cytotoxicity 
of MTX was tested on several human cancer cell lines. 
All proved sensitive to MTX with comparable EC50, 
with the exception of the human breast cancer cell line 
MDA-MB 231, which was less sensitive to MTX than the 
others, including the breast cancer cell line MCF-7. We 
then compared the internalization and cytotoxicity of free 
and NT4-conjugated MTX in two breast cancer cell lines: 
MTX-resistant MDA-MB 231 and MTX-sensitive MCF-7. 
We found that by coupling MTX to NT4, cancer cell drug 
resistance to MTX could be by-passed. 
RESULTS
Synthesis of NT4-MTX
NT4 peptide was synthesized by the solid-phase 
method and conjugated with methotrexate. MTX could be 
coupled to NT4 using the two different carboxylic groups, 
α and γ of the glutamic acid, giving two regioisomers 
that could have different efficacy. We prepared both 
isomers by linking MTX to NT4 through an amide bond 
originating from the free carboxyl group in α or γ position 
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of the drug and the amine group of the peptide (Figure 1). 
Identity and purity of the final products, NT4-α-MTX 
and NT4-γ-MTX, were confirmed by analytical reverse-
phase chromatography on a Jupiter C18 column and mass 
spectrometry. 
Screening of human cancer cell line for MTX 
sensitivity
In order to select MTX-resistant cancer cells, MTX 
cytotoxicity was tested in different human cancer cell lines 
(Table 1). All screened cancer cells proved sensitive to 
MTX with comparable EC50 (about 10−8M) with the sole 
exception of human breast cancer cell line MDA-MB 231, 
which was less sensitive to MTX (EC50 5.06 × 10−7 M). 
The two human breast cancer cell lines, MDA-MB 231 
and MCF-7, which had different sensitivity to MTX, were 
then selected to test NT4-MTX for its ability to circumvent 
MTX resistance. 
Binding and internalization of NT4 in MTX-
sensitive and MTX-resistant human breast 
cancer cell lines 
Binding and cell internalization of NT4 peptide, 
conjugated with biotin and traced by streptavidin-FITC, 
was tested in MTX-sensitive MCF-7 and MTX-resistant 
MDA-MB 231 human breast cancer cells and proved 
identical in the two cell lines (Figure 2A). In a previous 
study we demonstrated that NT4 binding to its membrane 
targets on cancer cells is inhibited by heparin, which can 
also completely abolish NT4 selectivity toward human 
cancer tissues [16]. Flow cytometry analysis showed that 
binding of NT4 to MCF-7 and MDA-MB 231 cells was 
inhibited by heparin (Figure 2B) and by heparin binding 
proteins like Apolipoprotein E4 and Midkine (Figure 2C). 
This confirmed that binding of NT4 to MCF-7 and 
MDA-MB 231 is specific and mediated by the same NT4 
membrane receptors.
MTX transporters in MTX-sensitive and MTX-
resistant human breast cancer cell lines
Transport of folate compounds into mammalian 
cells can occur via receptor-mediated or carrier-mediated 
mechanisms. Three genetically distinct and functionally 
diverse transport systems are involved in membrane 
transport of folates into mammalian cells, including RFC, 
PCFT, and folate receptors. RFC is the major systemic 
transport system for antifolate drugs in cancer cells 
[26–29]. Modified expression of folate membrane 
transporter or receptors is a common event leading to 
cell resistance to antifolates [5–9]. Given the different 
sensitivity of the two breast cancer cell lines to MTX, 
we analyzed gene expression of human RFC, PCFT and 
the three major isoforms α, β, and γ of FR in MCF-7 and 
MDA-MB 231 cells by RT-PCR (Figure 3). The breast 
cancer cell line MCF-7 and MDA-MB 231 displayed 
similar expression of PCFT, FR α and FR γ, whereas 
MDA-MB 231 cells lacked expression of RFC, which was 
instead expressed in MCF-7. As already reported, FR β 
was not detected in either cell line (data not shown) [30]. 
The lack of RFC could account for the higher resistance of 
MDA-MB 231 to MTX cytotoxicity. 
Figure 1: Structures of NT4 peptide conjugated with methotrexate using Cα of Glu, (1) NT4-α-MTX and Cγ of Glu,  (2) NT4-γ-MTX. 
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Drug influx and efflux in MTX-sensitive and 
MTX-resistant human breast cancer cell lines
Internalization of MTX conjugated with fluorescein 
(fluo-MTX) was monitored in MTX-sensitive and MTX-
resistant human breast cancer cell lines by flow cytometry 
(Figure 4A). MCF-7 and MDA-MB 231 cells were 
incubated for 15, 30 and 60 min with 10 µM fluo-MTX 
and the green fluorescent signal was analyzed in 10,000 
cells. Fluo-MTX was more efficiently internalized in 
MCF-7 cells than in MDA-MB 231. As shown in Figure 4A, 
fluo-MTX signal in MCF-7 was 2.7-fold higher than in 
MDA-MB 231 after 1 hour of incubation.
Since the amount of drug retained in a cell is the 
resultant of internalization and export rates, we compared 
the general drug efflux ability of MDA-MB 231 and 
MCF-7 cells. Rhodamine 123 (Rho 123), a member of the 
rhodamine family of fluorescent dyes, has been used as a 
tracer for efflux membrane transport [31, 32]. Rho 123 is 
lipophilic and can be transported passively inside cells, 
although its internalization can also be at least partially 
mediated by membrane transporters. Rho 123 export out of 
cells is actively mediated by ABC transporters. It has been 
used for analyzing active cell drug export mechanisms and 
related MDR [33].
The transporter-mediated efflux of Rho 123 was 
measured by following Rho 123 green signal in MCF-7 and 
MDA-MB 231. Cells were incubated with 1 µM Rho 123 
for 10 minutes. After washing, fluorescence was monitored 
by flow cytometry (Figure 4B). Despite an initially higher 
fluorescent signal in MDA-MB 231 at time 0, the signal 
decrease at each time interval was similar in MDA-MB 231 
and MCF-7, indicating that drug efflux was comparable in 
the two cell lines.
Cytotoxicity of free and NT4-conjugated MTX in 
human breast cancer cell lines
The cytotoxicity of NT4-α-MTX and NT4-γ-
MTX was tested in human MTX-sensitive MCF-7 and 
MTX-resistant MDA-MB 231 cells (Figure 5). The 
regiochemistry of the conjugation of NT4 to MTX proved 
to have no impact on the overall cytotoxic effect, since the 
two regioisomers, NT4-α-MTX and NT4-γ-MTX, were 
completely identical in this test.
Cellular toxicity of NT4-α-MTX was then compared 
to that of the corresponding free drug in MDA-MB 231 and 
MCF-7 cells. MCF-7 cells were more sensitive than MDA-
MB 231 to unconjugated MTX (EC50 2.58 × 10−8 M and 
5.06 × 10−7 M, respectively). Nonetheless, NT4-α-MTX 
was slightly more effective in MDA-MB 231 than in MCF-7 
(EC50 5.81 × 10−7 M and 1.14 × 10−6 M, respectively) 
(Figure 6). EC50 of NT4-α-MTX in MCF-7 and MDA-
MB 231 was in line with that previously measured by 
us in different cell lines [12, 14] and also with the EC50 
of different chemotherapy drugs, when conjugated to 
NT4 [11, 14]. No cytotoxic effect was measured using 
unconjugated NT4 at the same concentrations (Figure 6C).
To confirm specificity of NT4-α-MTX cytotoxicity 
in MTX-sensitive and MTX-resistant cells, we analyzed 
the effect of heparin on the efficacy of NT4-α-MTX with 
respect to the free drug. MCF-7 and MDA-MB 231 cells 
were exposed to different concentration of NT4-α-MTX 
or MTX in the presence of 1 µM heparin, which had 
previously been confirmed as not affecting cancer cell 
growth (not shown), and cell growth was analyzed after 
6 days of incubation (Figure 7). Heparin significantly 
decreased cytotoxicity of NT4-α-MTX in both cell lines, 
whereas it did not affect cytotoxicity of unconjugated MTX. 
DISCUSSION
For years tumor-targeted therapy has been 
considered a necessary development in cancer therapy to 
overcome the toxicity of classical chemotherapy drugs, 
the low selectivity of which inevitably damages healthy 
tissues and systems. The basis of tumor-targeted agents 
resides in cancer-specific antigens and/or cell pathways, 
the targeting of which may allow selective killing of cancer 
cells by direct or indirect mechanisms. Unfortunately no 
Table 1: EC50 of MTX on several human cancer cell lines
Cell line EC50 of MTX
MCF-7 human breast adenocarcinoma 2.58 × 10−8 M
MDA-MB 231 human breast adenocarcinoma 5.06 × 10−7 M
T-24 human bladder carcinoma 8.07 × 10−8 M
PANC-1 human pancreatic carcinoma 2.34 × 10−8 M
HT29 human colon adenocarcinoma 6.09 × 10−8 M
A375 human melanoma 3.37 × 10−8 M
HT-1376 human bladder carcinoma 1.71 × 10−7 M
OVCAR-3 human ovarian carcinoma 8.95 × 10−8 M
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Figure 2: NT4 binding to MCF-7 and MDA-MB 231. (A) Binding (30’ incubation) and internalization (4 h incubation) of NT4 
(red) in MCF-7 (left panel) and MDA-MB 231 cells (right panel) analyzed by confocal microscopy. Nuclei were stained with DAPI (blue) 
and plasma membrane was stained with wheat germ agglutinin (green). (B and C) Flow cytometry analysis of NT4 binding to MCF-7 and 
MDA-MB 231 cells and its inhibition by different concentrations of heparin (B) or by heparin binding proteins Apolipoprotein E4 and 
Midkine (C). Florescence of cells without NT4 is taken as control. Data presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 
calculated using two-tailed Student t-test using GraphPad Prism 5.03 software. 
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universal specific tumor target, selectively expressed by all 
tumors at any differentiation grade, has yet been identified. 
The efficiency of tumor targeting agents is therefore linked 
to preliminary identification of their specific target in a 
given tumor and a given patient. Thus cancer-selective 
targeting agents with double diagnostic and therapeutic 
use, i.e. theranostics, are very convenient for effective 
personalized therapy. 
In a theranostic oncological approach, specific 
targeting agents, like antibodies, peptides or nanoparticles, 
are used as cancer-selective carriers for delivery of drugs, 
dyes or radioisotopes for in vitro and in vivo imaging, 
which may be followed or accompanied by cancer 
cell killing. For such an approach, molecular targets 
overexpressed on cancer cell membranes are particularly 
attractive since they may allow selective binding of the 
targeting agent to cancer cells. Binding of the theranostic 
agent to membrane targets may suffice for cancer cell 
imaging, whereas cell internalization is usually necessary 
for therapy. The internalization of a drug-armed carrier 
after binding to a cancer cell membrane target can have the 
important advantage of preserving cells that do not express 
the membrane target. Moreover, drug internalization 
through a target-mediated mechanism can overcome 
drug resistance when this is mediated by modifications of 
membrane drug transporters. 
Since the first approval of the tumor-targeted 
monoclonal antibody Rituximab by the FDA in 1997, 
several tumor-selective agents have been approved. The 
vast majority of the drugs presently available for targeted 
therapy are antibodies recognizing membrane antigens, 
however small molecules interfering with tumor biological 
pathways, like the kinase inhibitors, are also in clinical 
use [34]. More recently, peptides have also been proposed 
as cancer-selective targeting agents, and these may combine 
some advantages of small molecules and antibodies [35]. 
Peptides have small molecular mass, they are obtained by 
chemical synthesis and can easily be conjugated to drugs 
with a favorable carrier-drug ratio, which is the main limit 
of antibody-drug conjugate activity [36], and can have cell 
selectivity similar to antibodies [35].
The finding that peptides synthesized in branched 
form are resistant to circulating proteases and peptidases 
[37] and that they can easily be conjugated to different 
functional units without interfering with their biological 
action [10, 11] paved the way for their use as cancer 
theranostics. In previous papers we investigated cancer-
selective tetra-branched peptides, named NT4, which can 
be coupled to different functional units for cancer cell 
imaging or therapy. NT4 peptides bind to LRP receptors 
and to heparan sulfate chains on membrane proteoglycans 
and can be efficiently internalized by cancer cells 
expressing these membrane targets [10–17].
Since our demonstration that cell internalization of 
NT4 peptides conjugated to functional units is mediated 
by peptide-specific membrane receptors overexpressed by 
cancer cells [10–12, 15, 16], we set out to check whether 
NT4 could overcome cancer cell drug resistance by 
mediating drug internalization into cells by a drug-
transporter-independent mechanism. 
We selected MTX as carried drug because cancer 
cell resistance to antifolate is often caused by modification 
in activity or expression of membrane folate transporters. 
We tested several different human cancer cell lines for 
sensitivity to MTX and found similar EC50 for all except 
the human breast cancer cell line MDA-MB 231, which 
was about ten times less sensitive.
In order to test whether cell resistance to MTX 
could be overcome by conjugating the drug with NT4, 
we compared binding, internalization and cytotoxicity 
of free and carrier-bound MTX on two breast cancer cell 
lines, MTX-resistant MDA-MB 231 and MTX sensitive 
MCF-7. The two cell lines proved to have similar ability 
to bind and internalize NT4 peptides, as verified by 
confocal microscopy and flow cytometry. NT4 binding 
was abolished by heparin in both cell lines, and was also 
inhibited by the known heparin-binding proteins Midkine 
and, to a lower extent, Apolipoprotein E4, in line with 
Figure 3: Folate transporters in MTX-sensitive and MTX-resistant human breast cancer cell lines. Gene expression of 
human FR α, FR γ, RFC and PCFT in MCF-7 and MDA-MB 231 cell lines by RT-PCR. Human GAPDH was used as experimental control.
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what we had reported with different human cancer cell 
lines [16], demonstrating specific recognition of NT4 
membrane targets. On the contrary, internalization of 
MTX, as tested by flow cytometry using a fluorescein-
conjugated drug, was lower in MDA-MB 231 than in 
MCF-7. 
We proved that the lower intracellular MTX detected 
in the MTX-resistant MDA-MB 231 cells was due to 
lower internalization rather than higher extrusion by ABC 
transporters. In fact, the two cell lines had comparable 
efficiency in Rho 123 extrusion.
When we studied expression of all MTX folate 
transporters and receptors in both cell lines, we found 
that MDA-MB 231 did not express RFC, the inactivating 
mutations or deficient expression of which is known to 
be associated with cancer cell resistance to antifolates. 
This was not surprising since the MDA-MB 231 cell line 
was already known to be resistant to MTX due to lower 
expression of RFC [38, 39].
Since the defect in MTX internalization in MDA-
MB 231 is due to lack of expression of the main folate 
transporter, we investigated whether we could by-
pass MTX resistance in these cells by switching MTX 
internalization to a completely different receptor-mediated 
mechanism, allowed by coupling MTX to NT4 peptides. 
The regiochemistry of conjugation did not prove to be a 
discriminant for overall cytotoxic activity and indeed the 
cytotoxicity of NT4-MTX was very similar in the two 
cell lines, with the MTX resistant cell line MDA-MB 231 
becoming even more sensitive to NT4-MTX compared to 
the MTX sensitive MCF-7 cell line. 
The EC50 of NT4-MTX is in the range of 10−7 M 
in both MTX sensitive MCF-7 and MTX resistant MDA-
MB 231 cell lines. This value is about ten times lower 
Figure 4: Drug influx and efflux in MTX-sensitive and MTX-resistant human breast cancer cell lines. (A) Fluorescein-
MTX internalization in MCF-7 and MDA-MB 231 cells after 15, 30 and 60 min of incubation, as measured by flow cytometry. Data 
presented as median ± SD. (B) Rhodamine 123 signal on MCF-7 and MDA-MB 231 cells measured by flow cytometry. Cells were 
incubated for 10 minutes with Rho 123 and washed. Green fluoresce was monitored immediately (T0) and after 10, 20, 30, 45, 60, 90 and 
120 minutes by FACS Canto II. Data presented as median ± SD.
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than that of the free drug in MCF-7 cells and is almost 
identical to the EC50 of free MTX in MDA-MB 231. 
Although apparently disappointing, this result is in line 
with what we reported in previous papers on NT4-MTX 
in vitro cytotoxicity on different cell lines [12, 14] and also on 
in vitro cytotoxicity of NT4 conjugated with different 
drugs [11, 14]. In any case, when the same drug-armed 
NT4 peptides were tested in vivo in different animal 
models of human cancers, they resulted much more 
efficient than the correspondent unconjugated drug in 
inhibiting tumor growth or even inducing regression up 
to clearance of the disease [10, 12, 15]. We are convinced 
Figure 5: Cytotoxicity of NT4-α-MTX (dark grey) and NT4-γ-MTX (light grey) in MTX-resistant MDA-MB 231 (A) and MTX-sensitive 
MCF-7 (B) human breast cancer cell lines. Data presented as mean ± SD.
Figure 6: Cytotoxicity of NT4-α-MTX in MTX-sensitive and MTX-resistant human breast cancer cell lines; NT4-α-MTX (A) free MTX 
(B) and unconjugated NT4 (C) in MCF-7 and MDA-MB 231 cell lines. (D) EC50 of NT4-α-MTX and free MTX in MCF-7 and MDA-MB 
231 cells. Data presented as mean of six experiments ± SD.
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that MTX, when conjugated to the NT4 peptide carriers, 
is internalized with a different mechanism which depends 
on NT4 membrane receptors, and this causes the drop in 
EC50 of MTX as well as of different chemotherapy drugs. 
This switch to an NT4-mediated drug internalization 
brings cytotoxicity to be the same in sensitive and resistant 
cells. This is an advantage, and has to be considered 
together with the ability of NT4-conjugated drugs to be 
more potent than the free drug in animal models of human 
cancers, where we obtained reduction of tumor growth 
of 60%, 50% and even regression of tumor, with NT4-
MTX, NT4-5Fluorodeoxiuridine and NT4-Paclitaxel, 
respectively [10, 12, 15]. With all the drug-armed NT4 
we tested, the cytotoxic activity was lower than that of 
the free drug, when tested against tumor cells grown 
in vitro, but became higher when the same tumor cells were 
grafted in mice. We believe that this reproducible result is 
due to the selective binding of NT4 to cancer cells, which 
cannot be appreciated in vitro, where only cancer cells are 
present. We already knew then, that conjugation to NT4 
can modify the drug biodistribution providing an enhanced 
tumor accumulation and therefore good efficacy results. 
Now we can also say that conjugation of a chemotherapy 
drug to NT4, by allowing a different and drug-independent 
cell binding and internalization, can bring to the advantage 
of bypassing drug-resistance of cancer cells.
In conclusion, NT4 peptides seem to be extremely 
promising cancer-selective targeting agents that can be 
exploited as theranostics in personalized oncological 
applications. The present results show that NT4 peptides 
can overcome drug resistance, which is a big advantage 
for their application in oncology. 
MATERIALS AND METHODS
Peptide synthesis
Peptides were synthesized on an automated multiple 
synthesizer (MultiSynTech, Germany) by standard Fmoc 
chemistry. Protected L-amino acids and Tentagel-resin 
were purchased from Iris Biotech, Germany, DIPEA 
(N,N-diisopropylethylamine) from Merck and HBTU 
(O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate) from MultiSynTech. Coupling 
times, 1.5 h rt; Fmoc deprotection times: 20 min, rt. 
NT4-biotin was synthesized on Tentagel resin with 
Fmoc-Lys(biotin)-OH as first coupling step, and Fmoc-
PEG12-OH as second; two coupling steps with Fmoc-
Lys(Fmoc)-OH were then used to build the tetrameric core. 
Pyro-Glu-O-pentachlorophenylester (Bachem, Switzerland) 
was used for the last coupling step, since pyro-Glu is the 
N-terminal acid of the neurotensin sequence. 
Peptide conjugated with methotrexate was 
synthesized using Fmoc-Lys(Dde)-OH as the first 
amino acid on Tentagel resin and Fmoc-βAla-OH as 
the second amino acid. Two coupling steps with Fmoc-
Lys(Fmoc)-OH were used to build the core. Pyro-Glu-O-
pentachlorophenylester was the N-terminal acid. Once the 
sequence was completed, the Dde protective group was 
removed using 2% hydrazine in DMF (v/v) on resin and 
the free amino group was coupled with Fmoc–PEG12–
OH. The Fmoc group was then removed to enable 
coupling with Fmoc-L-Glu(tBu)-OH in the case of 1 and 
with Fmoc-L-Glu-OtBu in the case of 2. Finally Fmoc was 
removed and 4-[N-(2,4-diamino-6-pteridinylmethyl)-N-
Figure 7: Cytotoxicity of NT4-α-MTX in human breast cancer cell lines, with and without heparin; NT4-α-MTX and free-MTX in MCF-7 
(A and B) and MDA-MB 231 (C and D).
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methylamino]benzoic acid was conjugated using HBTU 
and DIPEA as coupling reagents. Once solid-phase 
synthesis was completed, the peptides were cleaved from 
the resin, deprotected and lyophilized.
HPLC purification was performed on a C18 Jupiter 
Phenomenex column (300 Å, 250 × 10 mm). Water (A) 
containing 0.1% TFA and acetonitrile (B) were used as 
eluents in a linear gradient, from 75% to 65% of A in 
40 min at flow rate of 4 ml/min. The compounds were 
characterized on MALDI-TOF mass spectrometer 
(Ultraflex III Bruker Daltonics).
1, NT4-α-MTX, C386 H604 N102 O99. MALDI-MS: 
8259,62 [M+H]+. RP-HPLC: tR = 18,80 min, purity > 99%.
2, NT4-γ-MTX, C386 H604 N102 O99. MALDI-MS: 
8253,81 [M+H]+. RP-HPLC: tR = 19,80 min, purity > 99%.
Cell cultures 
MCF-7 human breast adenocarcinoma, MDA-MB 
231 human breast adenocarcinoma, T-24 human bladder 
carcinoma, PANC-1 human pancreatic carcinoma, HT29 
human colon adenocarcinoma, A375 human melanoma, 
HT-1376 human bladder carcinoma and OVCAR-3 human 
ovarian carcinoma cells were grown in their recommended 
media supplemented with 10% fetal calf serum, 200 µg/ml 
glutamine, 100 µg/ml streptomycin, 60 µg/ml penicillin, 
and maintained at 37°C, 5% CO2. MDA-MB 231 was 
maintained at 37°C without CO2. Cell lines were purchased 
from ATCC.
Cytotoxicity
MCF-7 and MDA-MB 231 cells were plated 
at a density of 5 × 103 per well in 96-well microplates. 
Different concentrations of NT4-α-MTX, NT4-γ-MTX, 
MTX or NT4 were added 24 h after plating and cells were 
incubated for 6 days at 37°C. For the cytotoxicity assay 
with heparin, cells were exposed to different concentration 
of NT4-α-MTX or MTX, from 610 pM to 10 µM, in the 
presence of 1 µM heparin. Cell growth was analyzed after 6 
days of incubation at 37°C. Growth inhibition was assessed 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT). Cytotoxicity of drug-conjugated NT4 was 
compared with that of the corresponding free drugs. The 
experiment was performed twice in triplicate. EC50 values 
were calculated by non-linear regression analysis using 
Graph Pad Prism 5.03 software. Values from untreated 
controls gave 100% cell viability. 
Immunofluorescence
5 × 104 cells/well MCF-7 and MDA-MB 231 were 
seeded on 24-well plates, grown for 24 hours, and then 
incubated with NT4-biotin for 30 min at 37°C (2 μM in 
PBS-1% BSA), followed by incubation for 30 minutes 
with 0.5 μg/ml Streptavidin-Atto 550 at room temperature. 
The cells were then washed and grown in medium for 1, 
2 or 4 h at 37°C to allow peptide internalization. They 
were then fixed with 4% formalin in PBS and plasma 
membranes were stained with wheat germ agglutinin, 
Alexa Fluor 647 conjugate (2.5 µg/mL in TBS-1% BSA) 
incubated for 10 min at room temperature and the nuclei 
were stained with DAPI (0.5 μg/ml in TBS-1% BSA). 
Each step was followed by three washes in PBS. Peptide 
binding was analyzed by confocal laser microscope (Leica 
TCS SP5) with 380 λ ex and 450-470 λ em, 550 λ ex and 
570-590 λ em, 633 λ ex and 660-680 λ em for DAPI, Atto 
550 and Atto 647, respectively.
Flow cytometry
All experiments were performed using 2 × 105 
MCF-7 or MDA-MB 231 cells in 96 well U-bottom 
plates. All dilutions were performed in PBS, containing 
5 mM EDTA and 0.5% BSA. 10,000 events were 
evaluated in a BD FACS Canto II or a BD FACS Calibur 
(Becton Dickinson, NJ USA). The results were analyzed 
by FCS Express 6 Flow cytometry software.
Inhibition of NT4 binding by heparin was carried 
out incubating cells with 250 nM biotinylated NT4 
and various concentrations (20 µg/ml, 10 µg/ml and 
1 µg/ml) of heparin for 30 min at room temperature. 
Inhibition of NT4 binding by heparin binding proteins 
was carried out incubating cells with 250 nM biotinylated 
NT4 and 1 µM Midkine or Apolipoprotein E4 for 30 min 
at room temperature. Cells were finally incubated with 
1 µg/ml Streptavidin-FITC. 
Internalization of fluo-MTX was carried out 
incubating cells with 10 µM fluo-MTX for 15, 30 and 
60 min at room temperature. 
To analyze active cell drug export mechanisms, 
MCF-7 and MDA-MB 231 cells were exposed to 1 µM 
Rho 123 for 10 minutes, then washed twice with PBS-5 
mM EDTA-5% BSA to remove excess of Rho 123, and 
fluorescence was monitored immediately (T0) and after 
10, 20, 30, 45, 60, 90 and 120 minutes. Each step was 
followed by three washes in PBS-5 mM EDTA-0.5% 
BSA. P values were calculated using two-tailed Student’s 
t-test (99% confidence interval) using Graph Pad Prism 
5.03 software. P values were reported in figure legend.
Gene expression
Total RNA from 1 × 106 MCF-7 and MDA-MB 
231 cells was extracted using an RNeasy kit (QIAGEN, 
Germantown, MD, US) according to the manufacturer’s 
instructions. One step RT-PCR (QIAGEN) was applied for 
retrotranscription and human cDNA amplification of RFC 
(636 pb), PCFT (569 pb), FR-α (568 pb), FR-β (439 pb), 
FR-γ (400 pb) and GAPSH (207 pb). Human GAPDH was 
used as reference gene. The following oligonucleotides 
were used as primers: 
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RFC primers were 5′-TGAATTCCTGAGC 
CCAGTGACAAC-3′ (sense), 5′AGCACCAAGGATGAC 
CAGCAAT-3′ (antisense); PCFT primers were 5′-ACTC 
TACCCAGCCACTCTGAACTT-3′ (sense), 5′-GATGA 
CTGCTACACGTGTTGGGAA-3′ (antisense); FR- α 
primers were 5′-CCTGCAAACGGCATTTCATCCA-3′ 
(sense), 5′-GGAGCAGGAACCAAATAGTTGGGA-3′ 
(antisense); FR-β primers were 5′-CCTGGATGTGCC 
CTTATGCAAAGA-3′ (sense), 5′-TTATCCAAGCTGAG 
GGCAGGTAGT-3′ (antisense); FR-γ primers were 5′-GA 
CCTGCTCAATGTCTGCATGAAC-3′ (sense), 5′-CT 
GAGGTCCAATTCCAGCCTTTGT-3′ (antisense); 
GAPDH primers were 5′-TCCTCTGACTTCA 
ACAGCGACACC-3′ (sense), 5′-TCTCTCTTCCTCTTGT 
GCTCTTGG-3′ (antisense). The following PCR 
conditions were applied: for RFC 30 cycles of denaturation 
at 94°C for 60 s, annealing at 58°C for 60 s and extension 
at 72°C for 90 s; for PCFT, FR-α and FR-β 30 cycles 
of denaturation at 94°C for 60 s, annealing at 57°C for 
60 s and extension at 72°C for 90 s; for FR-γ 30 cycles of 
denaturation at 94°C for 60 s, annealing at 60°C for 60 s 
and extension at 72°C for 90 s; for GAPDH 28 cycles of 
denaturation at 94°C for 30 s, annealing at 60°C for 30 s 
and extension at 72°C for 30 s.
Abbreviations
MTX, methotrexate; RFC, reduced folate carrier; 
PCFT, proton-coupled folate transporter; FR, folate 
receptor; DHFR, dihydrofolate reductase; TS, thymidylate 
synthase; GAG, glycosaminoglycans; HSPG, heparan 
sulfate proteoglycans; LDLR, low density lipoprotein 
receptor; LRP, lipoprotein receptor-related proteins; fluo, 
fluorescein; Rho123, rhodamine 123.
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